A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

Conditions

• Metastatic Lung Cancer
• Non-Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) — DRUG
  Participant will receive an FDA approved immunotherapy according to usual routine practice.
• Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments) — DRUG
  Description something along the lines of Participant will receive an FDA approved chemotherapy according to usual routine practice.
• Ablative Hypofractionated Radiotherapy — RADIATION
  Participant will receive radiotherapy according to usual routine practice.

Study Details

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Key Dates

First listed

May 22, 2026

Start date

Dec 12, 2026

Status verified

May 2026

Primary completion

Jun 25, 2030

Completion

Jun 25, 2030

Study Design

Enrollment

39 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Radiotherapy (RT) + Immunotherapy
  Participants will receive standard immunotherapy of investigator's choice in combination with radiation treatment.
• Active Comparator: Standard Chemotherapy (Investigator's Choice")
  Participants will receive standard chemotherapy of investigator's choice.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 48 months ]

Locations (1)

Find similar trials in Chicago, IL

Related Studies

• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
  PHASE2 · Recruiting · Genentech, Inc. · Los Angeles, California
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  PHASE1 · Recruiting · AbbVie · Duarte, California
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
  PHASE2 · Recruiting · AstraZeneca · Little Rock, Arkansas
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  PHASE3 · Recruiting · AstraZeneca · Chandler, Arizona